Results 131 to 140 of about 510,210 (307)

Bladder cancer biomarkers

Exploration of Targeted Anti-tumor Therapy
Bladder cancer (BCa) is among the most frequently diagnosed urinary tract cancers, characterized by a high recurrence rate and significant clinical heterogeneity. Effective diagnosis and treatment of BCa demand continuous advancements in medical technologies, particularly given the limitations of classical methods such as cystoscopy and urine cytology.
Dominik Godlewski, Dorota Bartusik-Aebisher, Sara Czech, Jakub Szpara, David Aebisher   +4 more
openaire   +3 more sources

Piezo1 Channel Mediates Mechanically Programmable Drug Delivery to Potentiate Intravesical Chemotherapy

Advanced Science, EarlyView.
This study utilizes programmable mechanical pressure as a therapeutic enhancer to establish a mechano‐chemotherapy strategy. Controlled pressure activates the mechanosensitive ion channel Piezo1 in bladder cancer, triggering a calcium ion cascade that transiently and reversibly amplifies membrane permeability to chemotherapeutics.
Minghai Ma, Xing Li, Minxuan Jing, Zezhong Yang, Jiale He, Jianpeng Li, Xiao Liang, Yunzhong Jiang, Rou Huang, Yuanquan Zhang, Yuanchun Pu, Jiawei Xiu, Yutong Chen, Kaibo Mi, Pu Zhang, Lei Wang, Jinhai Fan   +16 more
wiley   +1 more source

Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response

Bladder Cancer
Background: Many studies investigated the prognostic or predictive relevance of single nucleotide polymorphisms (SNPs) in biologically plausible genes in urinary bladder cancer (UBC) patients. Most published SNP associations have never been replicated in
Anne J. Grotenhuis, Aleksandra M. Dudek, Gerald W. Verhaegh, Katja K. Aben, J. Alfred Witjes, Lambertus A. Kiemeney, Sita H. Vermeulen   +6 more
doaj   +1 more source

NQO1‐Mediated Anoikis Resistance and Immune Evasion Define a High‐Risk Multi‐Omic Subtype for Precision Management of T1 High‐Grade Bladder Cancer

Advanced Science, EarlyView.
Multi‐omic profiling of T1 high‐grade bladder cancer identifies a high‐risk subtype (T1HG1) driven by NQO1, which couples anoikis resistance with immune evasion. NQO1 orchestrates macrophage–T cell crosstalk suppression via CXCL9 modulation. Pharmacological NQO1 inhibition with skullcapflavone II enhances cisplatin efficacy, representing a promising ...
Bin Guo, Chunru Xu, Shufan Fu, Qiang Cheng, Juan Li, Linkuo Shang, Gaojie Li, Yang Yang, Ying Wang, Yanqing Gong, Shengwei Xiong, Jian Fan, Changwei Yuan, Mei Zhang, Yifan Zuo, Elena Papaleo, Yue Shi, Yuan Liang, Xuesong Li, Hongzhao Li, Weimin Ci   +20 more
wiley   +1 more source

Bladder Cancer Patient Advocacy: A Global Perspective

Bladder Cancer
Over the past 20 years, cancer patient advocacy groups have demonstrated that patient engagement in cancer care is essential to improving patient quality of life and outcomes.
Diane Zipursky Quale, Rick Bangs, Monica Smith, David Guttman, Tammy Northam, Andrew Winterbottom, Andrea Necchi, Edoardo Fiorini, Stephanie Demkiw   +8 more
doaj   +1 more source

Tumor‐Intrinsic ARHGEF3 Enhances Antitumor Immunity by Promoting T‐Cell Infiltration and Limiting Myeloid Cell‐Mediated Immunosuppression

Advanced Science, EarlyView.
ARHGEF3 is broadly downregulated across human cancers and correlates with patient prognosis. Tumor‐intrinsic ARHGEF3 activates the RHOA–ROCK–PTEN cascade to inhibit AKT signaling, thereby promoting chemokine‐driven T‐cell infiltration and relieving lipid‐mediated myeloid immunosuppression.
Yue Li, Lan Wang, Zihao Zhang, Chunmei Qian, Ning Li, Wei Huang, Qian Ba, Xiaojian Liu, Mayu Sun   +8 more
wiley   +1 more source

Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer

Bladder Cancer
There are few approved drugs available for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) and none have been approved in the twenty-first century.
Jonathan Jarow, V. Ellen Maher, Shenghui Tang, Amna Ibrahim, Geoffrey Kim, Rajeshwari Sridhara, Richard Pazdur   +6 more
doaj   +1 more source

Integrating Radiomics and Computational Pathology to Predict Early Recurrence of Pancreatic Ductal Adenocarcinoma and Uncover Its Biological Basis in Tumor Microenvironment

Advanced Science, EarlyView.
Accurate prediction of early recurrence in pancreatic ductal adenocarcinoma is vital for optimizing treatment. A novel, integrated radiomics‐pathology machine learning model successfully forecasts recurrence risks by analyzing preoperative CT images and computational pathology.
Sihang Cheng, Fuze Cong, Shenbo Zhang, Rui Lv, Wenjia Zhang, Xinyi Ke, Juncheng Wu, Zhonghe Zhao, Kui Zhao, Di Dong, Ruofan Zhang, Zhengyu Jin, Max Seidensticker, Zhiwei Wang, Huanwen Wu, Xianlin Han, Nan Hong, Huadan Xue   +17 more
wiley   +1 more source

Copper Depletion Nanoparticles Potentiate Cancer Immunotherapy by Avoiding Innate and Adaptive Immune Resistance

Advanced Science, EarlyView.
A mitochondria‐targeted copper depletion nanoplatform (CYN‐CDA@Alb) was developed to selectively disrupt tumor mitochondria copper, which then reprogrammed the tumor immune microenvironment by depressing PD‐L1 and CD47 expression simultaneously. By doing this, CYN‐CDA@Alb reversed radiotherapy‐induced immune tolerance, showing the potential usage of ...
Zaigang Zhou, Ke Li, Xuelan Li, Lei Yi, Zhengxiang Wang, Huan Ding, Sheng Wu, Feiyu Liu, Yuan Li, Rui Cheng, Jianliang Shen   +10 more
wiley   +1 more source

Bioorthogonal Fluorogenic Reporters for Noninvasive Imaging and Urinalysis of Immunotherapeutic Response in Renal Cell Carcinoma

Advanced Science, EarlyView.
This study reported renal‐clearable bio‐orthogonal near‐infrared fluorogenic probes (BGRs) that specifically imaging and urinalysis of granzyme B for dynamic evaluation of RCC immunotherapy. BGRs not only differentiate immunotherapeutic responses in orthotopic RCC mice, but also enable sensitive optical urinalysis of granzyme B in clinical specimens ...
Xingyue Yang, Baoshuai Liang, Liangmin Fu, Weiliang Deng, Yuyan Jiang, Weiping Xu, Jinwei Chen, Ya Zhou, Ke Wu, Jiaguo Huang   +9 more
wiley   +1 more source